25 articles for RJ Ife
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
16
SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties.
Glaxosmithkline
38
Reversible inhibitors of the gastric (H+/K+)-ATPase. 3. 3-substituted-4-(phenylamino)quinolines.
Smithkline Beecham Pharmaceuticals R&D
23
The inhibition of human cytomegalovirus (hCMV) protease by hydroxylamine derivatives.
Smithkline Beecham Pharmaceuticals
8
4-(2-PYRTOYL)-5-phenylthiazoles as novel non-bicyclic reversible inhibitors of the gastric H+/K+-atpase
TBA
4
CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.
Glaxosmithkline
23
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.
Glaxosmithkline
21
Identification of a novel series of selective 5-HT7 receptor antagonists.
Glaxosmithkline
34
The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.
Glaxosmithkline
36
Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones.
Glaxosmithkline
7
Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.
Glaxosmithkline
41
1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A(2).
Glaxosmithkline
1
The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2.
Glaxosmithkline
11
Diastereoselective synthesis, activity and chiral stability of cyclic alkoxyketone inhibitors of cathepsin K.
Smithkline Beecham Pharmaceuticals
29
Solid-phase synthesis of cyclic alkoxyketones, inhibitors of the cysteine protease cathepsin K.
Smithkline Beecham Pharmaceuticals
51
N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2.
Smithkline Beecham Pharmaceuticals
36
CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.
Smithkline Beecham Pharmaceuticals
40
2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2.
Smithkline Beecham Pharmaceuticals
34
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
Smithkline Beecham Pharmaceuticals
66
Reversible inhibitors of the gastric (H+/K+)-ATPase. 5. Substituted 2,4-diaminoquinazolines and thienopyrimidines.
Smithkline Beecham Pharmaceuticals R&D
124
Reversible inhibitors of the gastric (H+/K+)-ATPase. 4. Identification of an inhibitor with an intermediate duration of action.
Smithkline Beecham Pharmaceuticals R&D
21
Reversible inhibitors of the gastric (H+/K+)-ATPase. 1. 1-Aryl-4-methylpyrrolo[3,2-c]quinolines as conformationally restrained analogues of 4-(arylamino)quinolines.
Smith Kline & French Research
21
Reversible inhibitors of the gastric (H+/K+)-ATPase. 2. 1-Arylpyrrolo[3,2-c]quinolines: effect of the 4-substituent.
Smithkline Beecham Pharmaceuticals R&D
